Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject Male or female age ≥ 75, or ≥ 60 if dementia~* Subject infected with COVID 19 (confirmed by RT-PCR SARS-CoV-2 detectable less than 5 days old and clinical picture)~* Clinical manifestation of COVID 19 requiring hospitalization:~pneumopathy and/or upper airway infection and/or respiratory distress, confusion and/or encephalopathy and/or signs of encephalitis, walking disorders with ataxia and/or falls, digestive problem (diarrhea and/or vomiting)~* Subject affiliated to a social health insurance scheme~* Subject capable of understanding the objectives and risks of the research and of giving dated and signed informed consent, or agreement given by a trusted person, guardian or trustee.~* Subject who has been informed of the results of the prior medical examination~Exclusion Criteria:~* Patients with a negative RT-PCR SARS-CoV-2 result~* Patients with COVID19 pneumopathy requiring resuscitative breathing support~* Porphyria~* Kaliemia 3.5 mmol/l and 5.5 mmol/l~* Any reason why patient follow-up would be impossible during the study period~* Patient on Sartan (Telmisartan, Candesartan, Valsartan, etc...), another antihypertensive, Hydroxychloroquine or Chloroquine, or macrolides (Azithromycin, Clarythromycyin...) within the last 24 hours.~* Patient with a contraindication to one of the treatments proposed in the study~* Contraindication Hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, piperaquine, QT prolongation (\>470ms for men and \>480 ms for women), retinopathy, hypersensitivity to the active substances or to one of the excipients, known deficit in G6PD~* Contraindication Azithromycin: combination with ergot derivatives, combination with colchicine, patients at risk of developing cardiac arrhythmia (diagnosis of QTc interval prolongation (\>470ms for men and \>480 ms for women), severe hepatic impairment,severe cholestase, history of allergy to macrolides or any of the excipients used in this study, end-stage renal failure with a glomerular filtration rate (DFG) - 15 ml/min, patients with malignant hemopathies who have undergone an allograft of hematopoietic stem cells~* Contraindication Telmisartan: Combination with drugs containing aliskiren, severe hepatic impairment, biliary obstruction, hypersensitivity to the active substance or to any of the excipients used in this study.~* Subject under safeguard of justice

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
- Azithromycin (Type: EXPERIMENTAL): Patient will take 250mg of Azithromycin twice a day during 14 days
- Telmisartan (Type: EXPERIMENTAL): Patient will take 40mg of Telmisartan twice a day during 14 days
- Usual Care (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).